Prenylated Rab acceptor 1 domain family member 2 (PRAF2)

Prenylated Rab acceptor 1 domain family member 2 (PRAF2) is a four-transmembrane domain protein predominantly localized to the endoplasmic reticulum, implicated in vesicle-mediated protein trafficking from the ER to the Golgi apparatus[1][2]. PRAF2 is highly expressed in the brain, breast, lung, intestine, spleen, and pancreas, and is upregulated in several types of human cancers—including breast cancer, neuroblastoma, glioma, hepatocellular carcinoma, and esophageal carcinoma—where its elevated expression is often associated with increased tumor proliferation, migration, invasion, metastatic potential, and worse prognosis[1]. Biologically, PRAF2 participates in regulating cell proliferation, migration, and apoptotic processes, possibly through modulating Wnt/β-catenin signaling in some cancer contexts[1]. Though widely considered a promising therapeutic target and biomarker in oncology, no clinically approved drugs are currently known to selectively inhibit this protein[1][2].

Other names

PRA1 domain family member 2PRAF2JM4Yip6aJena-Muenchen 4PRA1 family protein 2Sfc20DXImx39e

no drugs targeting PRAF2; mechanism when considered as a target relates to inhibition of protein—gene knockdown studies reduce cancer cell proliferation and migration